Marieke Rosier

Mrs. Marieke Rosier


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2025 in Cells
Verified
Journal Article
Open access
PDF file
SHSz-Ying Hou
Sz-Ying Hou
SMSarah C. Macfarlane
Sarah C. Macfarlane
ATAriadna Gómez Torijano
Ariadna Gómez Torijano
HKHyejeong Rosemary Kim
Hyejeong Rosemary Kim
MRMarieke Rosier
Marieke Rosier
AGAnnica Gad
Annica Gad
While normal fibroblasts suppress tumor growth, during cancer initiation and progression, this capacity can be lost and even switched to tumor-promoting, for reasons that are not understood. In this study, we aimed to determine differences between patient-derived cancer-associated fibroblasts and fibroblasts from healthy breast tissue to identify if and how these changes stimulate Triple-negative breast cancer (TNBC). Two-dimensional and three-dimensional mono and co-cultures of TNBC cells with fibroblasts from healthy breast or TNBC were analyzed for cell contractility, migration, distribution, proliferation, and hyaluronan production by traction force microscopy, live cell imaging, flow cytometry, Western blot, and ELISA. In 3D spheroid co-culture, CAFs migrated into the tumor mass, mixing with tumor cells, whereas normal fibroblasts remained separate. In 2D, CAFs showed increased cell migration and contractile force, and, in both 2D and 3D co-culture, CAFs increased the proliferation of TNBC cells. CAFs showed increased production of hyaluronan, as compared to normal fibroblasts, and loss of hyaluronan synthase 2 reduced CAF-induced stimulation of TNBC proliferation. These findings suggest that increased production of hyaluronan by TNBC CAFs enhances their capacity to mix with and induce the proliferation of cancer cells, and that the production of hyaluronan by CAFs can be a future therapeutic target against TNBC.

30 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MRMarieke Rosier
Marieke Rosier
AKAnja Krstulović
Anja Krstulović
HKHyejeong Rosemary Kim
Hyejeong Rosemary Kim
NKNihardeep Kaur
Nihardeep Kaur
EEErhumuoghene Mary Enakireru
Erhumuoghene Mary Enakireru
AGAnnica Gad
Annica Gad
Background: The epithelial-to-mesenchymal transition (EMT) is a common feature in early cancer invasion. Increased vimentin is a canonical marker of the EMT; however, the role of vimentin in EMT remains unknown. Methods: To clarify this, we induced EMT in lung cancer cells with TGF-β1, followed by treatment with the vimentin-targeting drug ALD-R491, live-cell imaging, and quantitative proteomics. Results: We identified 838 proteins in the intermediate filament fraction of cells. TGF-β1 treatment increased the proportion of vimentin in this fraction and the levels of 24 proteins. Variants of fibronectin showed the most pronounced increase (137-fold), followed by regulators of the cytoskeleton, cell motility, and division, such as the mRNA-splicing protein SON. TGF-β1 increased cell spreading and cell migration speed, and changed a positive correlation between cell migration speed and persistence to negative. ALD-R491 reversed these mesenchymal phenotypes to epithelial and the binding of RNA-binding proteins, including SON. Conclusions: These findings present many new interactors of intermediate filaments, describe how EMT and vimentin filament dynamics influence the intermediate filament interactome, and present ALD-R491 as a possible EMT-inhibitor. The observations support the hypothesis that the dynamic turnover of vimentin filaments and their interacting proteins govern mesenchymal cell migration, EMT, cell invasion, and cancer metastasis.

2 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MRMarieke Rosier
Marieke Rosier
AKAnja Krstulović
Anja Krstulović
HKHyejeong Rosemary Kim
Hyejeong Rosemary Kim
NKNihardeep Kaur
Nihardeep Kaur
EEErhumuoghene Mary Enakireru
Erhumuoghene Mary Enakireru
AGAnnica Gad
Annica Gad
The Epithelial-to-mesenchymal transition (EMT) is a common feature in early cancer invasion. Increased vimentin is a canonical marker of the EMT, however, the role of vimentin in EMT remains unknown. To clarify this, we induced EMT in lung cancer cells with TGF-β1, followed by treatment with the vimentin-targeting drug ALD-R491, live-cell imaging and quantitative proteomics. We identified 838 proteins in the intermediate filament fraction of cells. TGF-β1-treatment increased the proportion of vimentin in this fraction, and the levels of 24 proteins. Variants of fibronectin showed the most pronounced, 137-fold increase, followed by regulators of the cytoskeleton, cell motility and division, such as the mRNA-splicing protein SON. TGF-β1 increased cell spreading, cell migration speed and changed a positive correlation between cell migration speed and persistence to negative. ALD-R491 reversed these mesenchymal phenotypes to epithelial and the binding of RNA-binding proteins, including SON. These findings present ALD-R491 as a possible EMT-inhibitor and describe how EMT and vimentin dynamics influence the interactome of intermediate filaments. The observations support the hypothesis that the dynamic turnover of vimentin filaments and their interacting proteins govern mesenchymal cell migration, EMT, cell invasion and cancer metastasis.